Mandate

Vinge assists Nuevolution in connection with Amgen’s cash offer

Vinge has assisted Nuevolution AB (publ) (“Nuevolution”) in connection with the cash offer to the shareholders in Nuevolution by Amgen Inc. (“Amgen”).

Nuevolution is a molecule drug discovery biotech company, listed on Nasdaq Stockholm. 

Amgen is one of the world’s leading biotechnology companies, with a vision deeply rooted in innovative science. Amgen’s shares are listed on Nasdaq in the United States.

Amgen offers SEK 32.50 in cash for every share in Nuevolution. The offer value amounts to approximately SEK 1,610 million.
 
Vinge’s team has primarily consisted of David Andersson, Dain Hård Nevonen, Ludvig Frithiof and William Kåge.

Related

Vinge represents IKEA Forestry Investment AB in connection with the acquisition of forest and land in Latvia

Vinge assists IKEA Forestry Investment AB (a company within the Inter IKEA group) in the acquisition of 100% of the shares in the two Latvian companies SIA "Latvijas Mežu Aģentūra" and SIA "Vadakstes Meži" (the “Companies") from Skogsfond Baltikum AB (publ). The Companies own a total of 8,080 hectares of forest and land in Latvia.
December 16, 2024

Vinge advises Abliva on the public offer from Pharming

Pharming Technologies B.V., a wholly owned subsidiary of Pharming Group N.V., has announced a public offer to the shareholders of Abliva AB (publ). The total value of the offer is approximately SEK 725 million.
December 16, 2024

Vinge advises Umia Sweden and other owners in connection with the sale of Umia Stockholm to Sandbäckens

Umia Stockholm AB was founded in 2016 by Jonas Hedlund, Rolf Danielsson, Ronnie Ketola and Göran Karlsson, and currently has around 60 employees and a turnover of SEK 190 million (2023). The company specialises in electricity, which accounts for 70 % of its business, and ventilation. As part of the acquisition, Umia Stockholm AB will be integrated into the Sandbäckens brand in the near future.
December 11, 2024